Bevacizumab in metastatic breast cancer: when may it be used?
about
Anti-angiogenesis therapy and gap junction inhibition reduce MDA-MB-231 breast cancer cell invasion and metastasis in vitro and in vivo.In vitro the behaviors of metastasis with suppression of VEGF in human bone metastatic LNCaP-derivative C4-2B prostate cancer cell line.Inhibition of VEGF and Angiopoietin-2 to Reduce Brain Metastases of Breast Cancer Burden.
P2860
Bevacizumab in metastatic breast cancer: when may it be used?
description
2011 nî lūn-bûn
@nan
2011 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մարտին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Bevacizumab in metastatic breast cancer: when may it be used?
@ast
Bevacizumab in metastatic breast cancer: when may it be used?
@en
type
label
Bevacizumab in metastatic breast cancer: when may it be used?
@ast
Bevacizumab in metastatic breast cancer: when may it be used?
@en
prefLabel
Bevacizumab in metastatic breast cancer: when may it be used?
@ast
Bevacizumab in metastatic breast cancer: when may it be used?
@en
P2093
P2860
P356
P1476
Bevacizumab in metastatic breast cancer: when may it be used?
@en
P2093
Clifford Hudis
Maura N Dickler
Shari B Goldfarb
P2860
P356
10.1177/1758834010397627
P577
2011-03-01T00:00:00Z